Ashkan Shoamanesh
@ash-shoamanesh.bsky.social
Stroke Neurologist at Hamilton Health Sciences
Associate Professor of Medicine (Div. of Neurology) at McMaster University
Director of Hemorrhagic Stroke Research Program & Senior Scientist at the Population Health Research Institute
Associate Professor of Medicine (Div. of Neurology) at McMaster University
Director of Hemorrhagic Stroke Research Program & Senior Scientist at the Population Health Research Institute
Thrilled to share that the OCEANIC-STROKE trial (NCT05686070) led by PHRI & Bayer AG, has successfully completed enrolment of over 12,300 participants with non-cardioembolic ischemic #stroke over a recruitment period of only 26-months!
🔗https://phri.ca/oceanicstroke/
🔗https://phri.ca/oceanicstroke/
April 23, 2025 at 11:35 PM
Thrilled to share that the OCEANIC-STROKE trial (NCT05686070) led by PHRI & Bayer AG, has successfully completed enrolment of over 12,300 participants with non-cardioembolic ischemic #stroke over a recruitment period of only 26-months!
🔗https://phri.ca/oceanicstroke/
🔗https://phri.ca/oceanicstroke/
Absolutely honoured to be delivering the inaugural Ralph Sacco Distinguished Lecture at the @universityofmiami.bsky.social 58th Neurology Update & Stroke Intensive Review. Huge thanks to Drs. Negar Asdaghi & Jose Romano for their generous invitation and gracious hospitality!
@macdeptmed.bsky.social
@macdeptmed.bsky.social
March 8, 2025 at 4:16 AM
Absolutely honoured to be delivering the inaugural Ralph Sacco Distinguished Lecture at the @universityofmiami.bsky.social 58th Neurology Update & Stroke Intensive Review. Huge thanks to Drs. Negar Asdaghi & Jose Romano for their generous invitation and gracious hospitality!
@macdeptmed.bsky.social
@macdeptmed.bsky.social
Congrats to Ken Butcher on successfully leading the ICH-ADAPT 2 RCT. Our results do not support the notion that BP lowering contributes to the majority of acute/subacute DWI lesions in patients with ICH. Alternative mechanisms need to be explored. #ISC2025
@ahascience.bsky.social
@ahascience.bsky.social
February 9, 2025 at 7:09 PM
Congrats to Ken Butcher on successfully leading the ICH-ADAPT 2 RCT. Our results do not support the notion that BP lowering contributes to the majority of acute/subacute DWI lesions in patients with ICH. Alternative mechanisms need to be explored. #ISC2025
@ahascience.bsky.social
@ahascience.bsky.social
Should patients with #stroke and device-detected subclinical #AFib (SCAF) be treated with OAC?
Our subgroup analyses of the ARTESIA RCT (@thelancet.bsky.social) provide novel insights indicating that OAC is beneficial in appropriately selected patients.
www.thelancet.com/journals/lan...
Our subgroup analyses of the ARTESIA RCT (@thelancet.bsky.social) provide novel insights indicating that OAC is beneficial in appropriately selected patients.
www.thelancet.com/journals/lan...
January 23, 2025 at 4:16 AM
Should patients with #stroke and device-detected subclinical #AFib (SCAF) be treated with OAC?
Our subgroup analyses of the ARTESIA RCT (@thelancet.bsky.social) provide novel insights indicating that OAC is beneficial in appropriately selected patients.
www.thelancet.com/journals/lan...
Our subgroup analyses of the ARTESIA RCT (@thelancet.bsky.social) provide novel insights indicating that OAC is beneficial in appropriately selected patients.
www.thelancet.com/journals/lan...
January 18, 2025 at 9:50 PM
Thrilled to announce that the #EnrichAF randomized trial completed enrolment of 948 patients in Q4 2024.
So grateful for the efforts of our global colleagues on reaching this milestone, who persevered despite many challenges along the way.
Follow-up is due to complete in Q1 2026. Stay tuned!
So grateful for the efforts of our global colleagues on reaching this milestone, who persevered despite many challenges along the way.
Follow-up is due to complete in Q1 2026. Stay tuned!
January 16, 2025 at 1:38 AM
Thrilled to announce that the #EnrichAF randomized trial completed enrolment of 948 patients in Q4 2024.
So grateful for the efforts of our global colleagues on reaching this milestone, who persevered despite many challenges along the way.
Follow-up is due to complete in Q1 2026. Stay tuned!
So grateful for the efforts of our global colleagues on reaching this milestone, who persevered despite many challenges along the way.
Follow-up is due to complete in Q1 2026. Stay tuned!